Botulinum toxin type B 10,000units/2ml solution for injection vials
Requires a prescription from a doctor or prescriber
Neurotoxin produced by fermentation of clostridium botulinum type B.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(9)
Needle and syringe programmes (PH52)
Urinary incontinence in women (QS77)
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
Rehabilitation after traumatic injury (NG211)
Lower urinary tract symptoms in men: management (CG97)
Chronic anal fissure: botulinum toxin type A injection (ESUOM14)
Parkinson's disease in adults (NG71)
Stroke rehabilitation in adults (NG236)
Multiple sclerosis in adults: management (NG220)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 10 · Randomised trials: 2 · 1949–2026
Showing all 30 studies, sorted by most relevant.
B. Bhakta, A. Cozens, A. Chamberlain, et al.
Journal of Neurology, Neurosurgery & Psychiatry, 2000
- Arm
- Disability Evaluation
- Muscle Spasticity
T. Ubhi, B. Bhakta, L. Ives, et al.
Archives of Disease in Childhood, 2000
- Walking
- Ankle Joint
- Cerebral Palsy
Yasaman Safarpour, B. Jabbari
Toxicon, 2018
- Botulinum Toxins
- Neuromuscular Agents
- Pain
A. B. Scott, R. Kennedy, H. Stubbs
Archives of ophthalmology, 1985
- Blepharospasm
- Botulinum Toxins
- Eyelid Diseases
F. Friedenberg, Amiya Palit, H. Parkman, et al.
The American Journal of Gastroenterology, 2008
- Gastric Emptying
- Injections
- Neuromuscular Agents
Marybeth A Grazko, Kathleen B. Polo, B. Jabbari
Neurology, 1995
- Botulinum Toxins
- Muscle Rigidity
- Muscle Spasticity
Leslie S Foster, L. Clapp, Marleigh Erickson, et al.
Neurology, 2001
- Pain Measurement
- Surveys and Questionnaires
- Spasm
V. Brooks
The Journal of Physiology, 1956
- Botulinum Toxins
- Clostridium botulinum
- Cytoplasm
B. Bhakta, J. Cozens, J. M. Bamford, et al.
Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Muscle Spasticity
- Arm
- Botulinum Toxins
M. Riccabona, M. Koen, M. Schindler, et al.
The Journal of urology, 2004
- Administration, Intravesical
- Urinary Bladder Diseases
- Meningomyelocele
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
2 found
Half-life
Not available
Mechanism
Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Memb…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 823 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:30929742
Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1
ATC M03AX01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Botulinum toxin type B
Matched from: Botulinum B toxin
Additional database identifiers
Drugs Product Database (DPD)
12854
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12643
GenAtlas
VAMP2
GeneCards
VAMP2
GenBank Gene Database
M36205
GenBank Protein Database
338632
UniProt Accession
VAMP2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12642
GenAtlas
VAMP1
GeneCards
VAMP1
GenBank Gene Database
M36200
GenBank Protein Database
338625
UniProt Accession
VAMP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11510
GenAtlas
SYT2
GeneCards
SYT2
GenBank Gene Database
AK090672
GenBank Protein Database
21748879
UniProt Accession
SYT2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Wikipedia article
group of eight neurotoxic proteins produced by Clostridium botulinum
Read on WikipediaATC classifications (Wikidata)
Linked open data from Wikidata (Q208413), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.